Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, signed in October 2024 and extended to a maximum of 24 months, remains limited to non-binding feasibility testing rather than a committed commercial license. Lilly retains termination rights with 30 days’ notice, and the deal explicitly separates evaluation from any subsequent licensing step. Recent developments, including Lilly’s separate exclusive long-acting injectable partnership with Camurus for incretin therapies and the absence of any disclosed progress or milestones toward a full SmartDepot license despite expanded CNS research, have reinforced trader skepticism. With the October 7 resolution deadline approaching and no confirmed deal announcement, the market-implied odds heavily favor “No.”
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour13% chance
$11,314 Vol.
$11,314 Vol.
6 oct. 2026
13% chance
$11,314 Vol.
$11,314 Vol.
6 oct. 2026
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, signed in October 2024 and extended to a maximum of 24 months, remains limited to non-binding feasibility testing rather than a committed commercial license. Lilly retains termination rights with 30 days’ notice, and the deal explicitly separates evaluation from any subsequent licensing step. Recent developments, including Lilly’s separate exclusive long-acting injectable partnership with Camurus for incretin therapies and the absence of any disclosed progress or milestones toward a full SmartDepot license despite expanded CNS research, have reinforced trader skepticism. With the October 7 resolution deadline approaching and no confirmed deal announcement, the market-implied odds heavily favor “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Marché ouvert : May 5, 2026, 8:02 PM ET
Volume
$11,314Date de fin
7 oct. 2026Marché ouvert
May 5, 2026, 8:02 PM ETRésolveur
0x65070BE91...This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, signed in October 2024 and extended to a maximum of 24 months, remains limited to non-binding feasibility testing rather than a committed commercial license. Lilly retains termination rights with 30 days’ notice, and the deal explicitly separates evaluation from any subsequent licensing step. Recent developments, including Lilly’s separate exclusive long-acting injectable partnership with Camurus for incretin therapies and the absence of any disclosed progress or milestones toward a full SmartDepot license despite expanded CNS research, have reinforced trader skepticism. With the October 7 resolution deadline approaching and no confirmed deal announcement, the market-implied odds heavily favor “No.”
This market will resolve to “Yes” if Eli Lilly signs a commercial licensing agreement, technology transfer agreement, or equivalent binding agreement with Peptron that grants Eli Lilly commercial rights to Peptron’s SmartDepot technology by the specified date, 11:59 PM Korea Standard Time. Otherwise, this market will resolve to “No”.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Only commercial licensing agreements, technology transfer agreements, or equivalent binding agreements that grant Eli Lilly direct commercial rights to develop, manufacture, sell, or otherwise commercialize Peptron’s SmartDepot technology will qualify.
Co-development agreements will not qualify. Extensions of the existing Technology Evaluation Agreement or other agreements which are non-binding or do not grant Eli Lilly direct commercial rights to SmartDepot will not qualify.
The primary resolution source for this market will be official information from Eli Lilly and Peptron; however, a consensus of credible reporting may also be used.
Volume
$11,314Date de fin
7 oct. 2026Marché ouvert
May 5, 2026, 8:02 PM ETRésolveur
0x65070BE91...Eli Lilly’s ongoing technology evaluation agreement with Peptron for the SmartDepot sustained-release microsphere platform, signed in October 2024 and extended to a maximum of 24 months, remains limited to non-binding feasibility testing rather than a committed commercial license. Lilly retains termination rights with 30 days’ notice, and the deal explicitly separates evaluation from any subsequent licensing step. Recent developments, including Lilly’s separate exclusive long-acting injectable partnership with Camurus for incretin therapies and the absence of any disclosed progress or milestones toward a full SmartDepot license despite expanded CNS research, have reinforced trader skepticism. With the October 7 resolution deadline approaching and no confirmed deal announcement, the market-implied odds heavily favor “No.”
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes